Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 14/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.37 |
| ▸ | EIF4E | P06730 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21629673 | 0.87 | EIF4E (0.41) | EIF4E | |
| SCHEMBL21629658 | 0.84 | NR1H2 (0.43) | NR1H2CA12CA9BRD4CREBBP | |
| SCHEMBL21629666 | 0.78 | NR1H2 (0.47) | NR1H2CA12CA9BRD4CREBBP | |
| SCHEMBL9846756 | 0.77 | NR1H2 (0.48) | NR1H2CA12CA9BRD4CREBBP | |
| SCHEMBL29891011 | 0.75 | NR1H2 (0.38) | NR1H2BRD4CREBBPNR1H3 | |
| SCHEMBL22829307 | 0.75 | NR1H2 (0.38) | NR1H2BRD4CREBBPNR1H3 | |
| SCHEMBL21657932 | 0.75 | TTK (0.47) | NR1H2BRD4CREBBPNR1H3 | |
| SCHEMBL9846769 | 0.72 | NR1H2 (0.48) | NR1H2CA12CA9BRD4CREBBP | |
| SCHEMBL29891226 | 0.72 | NR1H2 (0.41) | NR1H2CA12CA9BRD4CREBBP | |
| SCHEMBL21657878 | 0.71 | NR1H2 (0.39) | NR1H2CA12CA9BRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200031805-A1 | ARYL HYDROCARBON RECEPTOR (AHR) MODULATOR COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031805-A1 | ARYL HYDROCARBON RECEPTOR (AHR) MODULATOR COMPOUNDS | AHR, ARNT, AIPL1 | NR1H2 5/4885CA12 4740/4885CA9 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.